Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties

English version České info

The HIV envelope glycoprotein (Env) is the sole virally encoded gene product on the surface of the virus and, as such, is the only target of neutralizing antibodies. A broadly efficacious HIV vaccine will likely need to generate a robust neutralizing antibody response directed at conserved elements of the variable Env. For a successful antibody-based vaccine, a soluble mimic of the HIV spike will likely be required to generate high-titer anti-Env antibodies capable of neutralizing a wide array of HIV isolates. Due to the global sequence diversity of Env, generating a diverse array of these soluble spikes will benefit immunization strategies designed to cope with such viral diversity. Here, we report a novel purification strategy followed by a comprehensive characterization of two soluble HIV spikes from infection-prominent subtypes, B and C. We demonstrate that these homogeneous soluble trimers are faithful mimics of the HIV spike by neutralizing antibody binding, electron microscopy and other biophysical assessments. Possessing soluble and stable mimics of the HIV spike derived from diverse strains improves both our knowledge of HIV spike architecture as shown here and extends subtype coverage of potential vaccine candidates.

Vyšlo v časopise: Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties. PLoS Pathog 11(1): e32767. doi:10.1371/journal.ppat.1004570
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004570

Souhrn

Zdroje

1. WyattR, SodroskiJ (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884–1888.

2. DalgleishAG, BeverleyPC, ClaphamPR, CrawfordDH, GreavesMF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763–767.

3. McDougalJS, NicholsonJK, CrossGD, CortSP, KennedyMS, et al. (1986) Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J Immunol 137: 2937–2944.

4. Karlsson HedestamGB, FouchierRA, PhogatS, BurtonDR, SodroskiJ, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143–155.

5. BurtonDR, DesrosiersRC, DomsRW, KoffWC, KwongPD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233–236.

6. WuX, YangZY, LiY, HogerkorpCM, SchiefWR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861.

7. WalkerLM, PhogatSK, Chan-HuiPY, WagnerD, PhungP, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.

8. WalkerLM, HuberM, DooresKJ, FalkowskaE, PejchalR, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470.

9. HuangJ, OfekG, LaubL, LouderMK, Doria-RoseNA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412.

10. ScharfL, ScheidJF, LeeJH, WestAPJr, ChenC, et al. (2014) Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7: 785–795.

11. KleinF, GaeblerC, MouquetH, SatherDN, LehmannC, et al. (2012) Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 209: 1469–1479.

12. MascolaJR, LewisMG, StieglerG, HarrisD, VanCottTC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009–4018.

13. HessellAJ, RakaszEG, PoignardP, HangartnerL, LanducciG, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.

14. MoldtB, RakaszEG, SchultzN, Chan-HuiPY, SwiderekK, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109: 18921–18925.

15. BarouchDH, WhitneyJB, MoldtB, KleinF, OliveiraTY, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503: 224–228.

16. BurtonDR, HessellAJ, KeeleBF, KlassePJ, KetasTA, et al. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108: 11181–11186.

17. SundlingC, LiY, HuynhN, PoulsenC, WilsonR, et al. (2012) High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 4: 142ra196.

18. TranK, PoulsenC, GuenagaJ, de ValN, WilsonR, et al. (2014) Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A 111: E738–747.

19. HaynesBF, GilbertPB, McElrathMJ, Zolla-PaznerS, TomarasGD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275–1286.

20. Zolla-PaznerS, deCampA, GilbertPB, WilliamsC, YatesNL, et al. (2014) Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 9: e87572.

21. JonesNG, DeCampA, GilbertP, PetersonML, GurwithM, et al. (2009) AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27: 1136–1140.

22. Rerks-NgarmS, PitisuttithumP, NitayaphanS, KaewkungwalJ, ChiuJ, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220.

23. YatesNL, LiaoHX, FongY, deCampA, VandergriftNA, et al. (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6: 228ra239.

24. RingeRP, SandersRW, YasmeenA, KimHJ, LeeJH, et al. (2013) Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 110: 18256–18261.

25. ChakrabartiBK, FengY, SharmaSK, McKeeK, Karlsson HedestamGB, et al. (2013) Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J Virol 87: 13239–13251.

26. KovacsJM, NkololaJP, PengH, CheungA, PerryJ, et al. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 109: 12111–12116.

27. NkololaJP, CheungA, PerryJR, CarterD, ReedS, et al. (2014) Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine 32: 2109–2116.

28. LyumkisD, JulienJP, de ValN, CupoA, PotterCS, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342: 1484–1490.

29. JulienJP, CupoA, SokD, StanfieldRL, LyumkisD, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477–1483.

30. SandersRW, DerkingR, CupoA, JulienJP, YasmeenA, et al. (2013) A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9: e1003618.

31. DepetrisRS, JulienJP, KhayatR, LeeJH, PejchalR, et al. (2012) Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 287: 24239–24254.

32. BartesaghiA, MerkA, BorgniaMJ, MilneJL, SubramaniamS (2013) Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 20: 1352–1357.

33. BinleyJM, SandersRW, ClasB, SchuelkeN, MasterA, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627–643.

34. SandersRW, VesanenM, SchuelkeN, MasterA, SchiffnerL, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875–8889.

35. KlassePJ, DepetrisRS, PejchalR, JulienJP, KhayatR, et al. (2013) Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 87: 9873–9885.

36. PanceraM, WyattR (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332: 145–156.

37. McLellanJS, PanceraM, CarricoC, GormanJ, JulienJP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336–343.

38. JulienJP, LeeJH, CupoA, MurinCD, DerkingR, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 110: 4351–4356.

39. HoffenbergS, PowellR, CarpovA, WagnerD, WilsonA, et al. (2013) Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol 87: 5372–5383.

40. LiuJ, BartesaghiA, BorgniaMJ, SapiroG, SubramaniamS (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109–113.

41. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, et al.. (2014) Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. Immunity.

42. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, et al.. (2014) Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity.

43. WalkerLM, PhogatSK, Chan-HuiPY, WagnerD, PhungP, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.

44. LiY, O'DellS, WilsonR, WuX, SchmidtSD, et al. (2012) HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol 86: 11231–11241.

45. SokD, DooresKJ, BrineyB, LeKM, Saye-FranciscoKL, et al. (2014) Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Sci Transl Med 6: 236ra263.

46. KhayatR, LeeJH, JulienJP, CupoA, KlassePJ, et al. (2013) Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 87: 9865–9872.

47. BinleyJM, SandersRW, MasterA, CayananCS, WileyCL, et al. (2002) Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76: 2606–2616.

48. Doria-RoseNA, GeorgievI, O'DellS, ChuangGY, StaupeRP, et al. (2012) A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 86: 8319–8323.

49. DooresKJ, BurtonDR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510–10521.

50. KirschnerM, MonroseV, PaluchM, TechodamrongsinN, RethwilmA, et al. (2006) The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 48: 61–68.

51. VossNR, YoshiokaCK, RadermacherM, PotterCS, CarragherB (2009) DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol 166: 205–213.

52. LanderGC, StaggSM, VossNR, ChengA, FellmannD, et al. (2009) Appion: an integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol 166: 95–102.

53. SorzanoCO, Bilbao-CastroJR, ShkolniskyY, AlcorloM, MeleroR, et al. (2010) A clustering approach to multireference alignment of single-particle projections in electron microscopy. J Struct Biol 171: 197–206.

54. van HeelM, HarauzG, OrlovaEV, SchmidtR, SchatzM (1996) A new generation of the IMAGIC image processing system. J Struct Biol 116: 17–24.

55. TangG, PengL, BaldwinPR, MannDS, JiangW, et al. (2007) EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol 157: 38–46.

56. LudtkeSJ, BaldwinPR, ChiuW (1999) EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128: 82–97.

57. PettersenEF, GoddardTD, HuangCC, CouchGS, GreenblattDM, et al. (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25: 1605–1612.